Table 1 Description and demographics for the 2020–2021 cohort
From: Long COVID involves activation of proinflammatory and immune exhaustion pathways
NCs (n = 35) | Acute COVID 19+ infection (n = 54) | CCs (n = 24) | LCs (n = 28) | |
|---|---|---|---|---|
Age | Median: 63 | Median: 65.75 | Median: 50.05 | Median: 50.50 |
95% CI | 95% CI | 95% CI | 95% CI | |
(54.39–66.71) | (59.57–69.07) | (46.28–59.21) | (45–56.15) | |
Gender | ||||
Male | 18 (51.42%) | 27 (50%) | 10 (40%) | 4 (14.29%) |
Female | 17 (48.57%) | 27 (50%) | 15 (60%) | 24 (85.71%) |
Ethnicity | ||||
Asian | 2 (5.71%) | ND | 0 (0%) | ND |
Black | 6 (17.14%) | ND | 5 (20%) | ND |
White | 22 (62.85%) | ND | 11 (44%) | ND |
Hispanic | 5 (14.28%) | ND | 2 (8%) | ND |
Not Hispanic or Latino | 0 (0%) | ND | 7 (28%) | 28 (100%) |
Number of days to first COVID+ | NA | Median: 14 | Median: 71 | Median: 200 |
95% CI | 95% CI | 95% CI | ||
(11.6–16.40) | (44.67–97.33) | (178.27–221.73) | ||
Vaccine | NA | NA | ||
Moderna | 3 (12%) | 12 (42.85%) | ||
Pfizer | 2 (8%) | 12 (42.85%) | ||
Unknown | 2 (8%) | 4 (14.28%) | ||
No vaccine | 18 (72%) | 0 (0%) | ||
